A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

NCT01652144 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NETWORK

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: AT7519M

Sponsor

NCIC Clinical Trials Group

Collaborators

[object Object]